Will a large rapamycin/rapalog trial in older adults show a convincing signal on immune resilience, frailty, or functional endpoints before 2028?

This is a ClinicalTrials.gov registry entry for a rapamycin trial in frail older adults, directly relevant because it tests functional and frailty-adjacent outcomes in the target population. It bears on the prediction as a potential source of pre-2028 trial results showing whether rapamycin produces a statistically significant signal on stated endpoints.

This is a March 16, 2026 UT Health San Antonio news release announcing the launch of a large NIA-funded rapamycin clinical study in older adults. It is relevant because it is direct evidence that a qualifying large trial is underway, which bears on the likelihood of reported endpoint results before the 2027-12-31 resolution horizon.

This is a UT Health San Antonio news release announcing the launch of a clinical trial studying rapamycin and healthy aging in older adults. It is relevant because it provides evidence that a potentially large rapamycin trial tied to the prediction is underway, though it does not report endpoint results.

This is a 2016 peer-reviewed pilot study in older adults with coronary artery disease evaluating low-dose rapamycin on senescence markers and physical functioning. It is relevant because it provides early human evidence on rapamycin-related functional and aging-associated endpoints, which informs the plausibility of later large trials showing signals before 2028, even though it is not itself a large definitive trial.

This appears to be a Healthspan-hosted article summarizing an ongoing large human rapamycin trial in older adults, including design details such as dose, safety framing, and intended endpoints. It is relevant because it supports the existence and scope of a large trial that could resolve the prediction, but it is not itself a registry entry or results publication.

This is a University of Arizona Foundation news page announcing the launch of a rapamycin clinical trial in aging. It bears on the prediction because it is evidence that a human trial in older adults is being organized and funded before 2028, though it does not report efficacy results or endpoint outcomes.

This is a news item reporting the launch of a large Phase 3 rapamycin trial in healthy aging. It is relevant because it indicates a substantial late-stage study exists that could plausibly generate statistically significant immune resilience, frailty, or functional endpoint results before 2028, though it is not itself a results report.

This is a ClinicalTrials.gov registry entry for the REACH rapamycin trial, which appears to study rapamycin in older adults with aging-related cognitive outcomes. It bears on the prediction as pipeline evidence that a human rapamycin trial in an older population is underway, though it is not itself a results report and is not directly focused on immune resilience or frailty endpoints.

This appears to be a PMC-hosted article about a sirolimus (rapamycin) intervention in older adults, directly aligned with the forecasted class of large rapamycin/rapalog trials on resilience or functional aging outcomes. Even without full-page access, the title and source strongly indicate genuine trial-related evidence bearing on whether such a study reports a meaningful endpoint signal before 2028.

This appears to be a secondary news/explainer article on Healthspan describing an ongoing large rapamycin trial in older adults, including its design, dose, and intended clinical endpoints. It bears on the forecast because it is evidence that a large trial exists and is positioned to generate publishable endpoint data before 2028, but it is not itself a registry record or results publication.

This appears to be a peer-reviewed perspective/review article about clinical development of rapamycin/rapalogs for aging-related indications. It is relevant because it discusses the trial landscape, including large studies in older adults, which informs the likelihood that a qualifying trial could report a significant signal before 2028, even though it is not itself a trial result.